{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:05:17Z","timestamp":1785247517883,"version":"3.55.0"},"reference-count":190,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Lipoprotein(a) (Lp(a)) is increasingly recognized as a genetically determined and clinically relevant contributor to residual cardiovascular risk. Through pro-atherogenic, pro-inflammatory, pro-thrombotic, and pro-calcific mechanisms, Lp(a) appears to play a significant role in both coronary artery disease and aortic valve disease. In patients undergoing percutaneous coronary intervention, elevated Lp(a) has been associated with worse long-term outcomes, including recurrent ischemic events, repeat revascularization, and in-stent restenosis, even in the setting of controlled low-density lipoprotein cholesterol. In parallel, experimental, genetic, and clinical data support a role for Lp(a) in the initiation and progression of calcific aortic stenosis, while its prognostic significance after transcatheter aortic valve interventions remains less clearly defined. Current guidelines now recognize Lp(a) as a relevant risk-enhancing factor, and emerging targeted therapies are achieving substantial reductions in circulating levels. Overall, Lp(a) should be regarded as both a meaningful biomarker and a promising therapeutic target, although ongoing outcome trials are needed to determine whether selective Lp(a) lowering translates into clinical benefit across interventional cardiovascular settings. The aim of this narrative review is to provide a single, comprehensive account of lipoprotein(a) [Lp(a)] in interventional cardiology, following this lipoprotein from its biology and pathophysiology through to its clinical impact and to the therapies that are now reaching the clinic, with a specific focus on the two most frequent catheter-based procedures in which it may carry prognostic weight: percutaneous coronary intervention (PCI) and transcatheter aortic valve implantation (TAVI). PCI and TAVI are deliberately addressed within the same review since they share a common upstream biology: Lp(a) contributes both to the atherosclerotic process that underlies coronary disease and to the calcific process that underlies aortic valve disease, and the corresponding patient populations overlap considerably in everyday interventional practice. Covering them together offers the interventional cardiologist a single, practical reference on how a patient with elevated Lp(a) may be approached in both scenarios.<\/jats:p>","DOI":"10.3390\/jcm15155897","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:07:33Z","timestamp":1785244053000},"page":"5897","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5441-9276","authenticated-orcid":false,"given":"Francesco Maria","family":"Animati","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze Cardiovascolari e Pneumologiche, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Proietti","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Cardiovascolari e Pneumologiche, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Auletta","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Cardiovascolari e Pneumologiche, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-1018","authenticated-orcid":false,"given":"Rocco Antonio","family":"Montone","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine\u2014CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6905-9268","authenticated-orcid":false,"given":"Luigi","family":"Cappannoli","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine\u2014CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fracassi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine\u2014CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Gaspardone","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Sant\u2019Eugenio Hospital, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Burzotta","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Cardiovascolari e Pneumologiche, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Department of Cardiovascular Medicine\u2014CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A NEW SERUM TYPE SYSTEM IN MAN\u2014THE LP SYSTEM","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol. Microbiol. Scand."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/01.CIR.95.2.295","article-title":"Lipoprotein(a), a Clinically Elusive Lipoprotein Particle","volume":"95","author":"Fortmann","year":"1997","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1399-0004.1974.tb00657.x","article-title":"Lp(a) Lipoprotein and Pre-Beta1-Lipoprotein in Patients with Coronary Heart Disease","volume":"6","author":"Berg","year":"1974","journal-title":"Clin. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"CDNA Sequence of Human Apolipoprotein(a) Is Homologous to Plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12170-025-00760-1","article-title":"Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease","volume":"19","author":"Doherty","year":"2025","journal-title":"Curr. Cardiovasc. Risk Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5339\/gcsp.2015.28","article-title":"High Prevalence of Raised Lipoprotein(a) in Patients with Refractory Angina","volume":"2015","author":"Khan","year":"2015","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jacc.2024.06.015","article-title":"Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions","volume":"84","author":"Montone","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration, Erqou, S., Kaptoge, S., Perry, P.L., Di Angelantonio, E., Thompson, A., White, I.R., Marcovina, S.M., Collins, R., and Thompson, S.G. (2009). Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA, 302, 412\u2013423.","DOI":"10.1001\/jama.2009.1063"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients with or Without Baseline Atherosclerotic Cardiovascular Disease","volume":"83","author":"Berman","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14779072.2024.2387678","article-title":"Lipoprotein(a) in Interventional Cardiology: Identifying Patients at Highest Risk of Recurrent Cardiovascular Events through Early Recognition\u2014A Case Based Review","volume":"22","author":"Renkens","year":"2024","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_12","first-page":"27","article-title":"All We Need to Know about Lipoprotein(a)","volume":"84","author":"Bess","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-pharmtox-031023-100609","article-title":"LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics","volume":"64","author":"Tasdighi","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.1021\/bi962433d","article-title":"The Solution Phase Interaction between Apolipoprotein(a) and Plasminogen Inhibits the Binding of Plasminogen to a Plasmin-Modified Fibrinogen Surface","volume":"36","author":"Sangrar","year":"1997","journal-title":"Biochemistry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1194\/jlr.M036566","article-title":"Inhibition of Plasminogen Activation by Apo(a): Role of Carboxyl-Terminal Lysines and Identification of Inhibitory Domains in Apo(a)","volume":"55","author":"Romagnuolo","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_16","first-page":"76","article-title":"Lipoprotein (a): Structure, Pathophysiology and Clinical Implications","volume":"103","author":"Carvalho","year":"2014","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0005-2760(79)90131-0","article-title":"Lipoprotein (a) Is Not a Metabolic Product of Other Lipoproteins Containing Apolipoprotein B","volume":"575","author":"Krempler","year":"1979","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3491764","DOI":"10.1155\/2020\/3491764","article-title":"Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule","volume":"2020","author":"Jawi","year":"2020","journal-title":"J. Lipids"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) Metabolism: Potential Sites for Therapeutic Targets","volume":"62","author":"Huang","year":"2013","journal-title":"Metabolism"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Brosolo, G., Da Porto, A., Marcante, S., Picci, A., Capilupi, F., Capilupi, P., Bulfone, L., Vacca, A., Bertin, N., and Vivarelli, C. (2023). Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713363"},{"key":"ref_21","first-page":"202505","article-title":"Lipoprotein(a) Assembly\u2013Diagnostic and Therapeutic Implications","volume":"1","author":"Dieplinger","year":"2026","journal-title":"Adv. Lipoprotein (a) Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00041433-199906000-00005","article-title":"Lipoprotein(a): Intrigues and Insights","volume":"10","author":"Hobbs","year":"1999","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1042\/bj3040027","article-title":"Structural Requirements of Apo-a for the Lipoprotein-a Assembly","volume":"304","author":"Frank","year":"1994","journal-title":"Biochem. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"28716","DOI":"10.1016\/S0021-9258(19)61964-2","article-title":"Cell Surface Assembly of Lipoprotein(a) in Primary Cultures of Baboon Hepatocytes","volume":"269","author":"White","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/eurheartj\/eht053","article-title":"When Should We Measure Lipoprotein (a)?","volume":"34","author":"Kostner","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11643","DOI":"10.1073\/pnas.90.24.11643","article-title":"Cys4057 of Apolipoprotein(a) Is Essential for Lipoprotein(a) Assembly","volume":"90","author":"Brunner","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.metabol.2015.10.031","article-title":"Distinct Metabolism of Apolipoproteins (a) and B-100 within Plasma Lipoprotein(a)","volume":"65","author":"Diffenderfer","year":"2016","journal-title":"Metabolism"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11883-013-0360-6","article-title":"Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator","volume":"15","author":"Boffa","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.atherosclerosis.2012.09.031","article-title":"In Vivo Stable-Isotope Kinetic Study Suggests Intracellular Assembly of Lipoprotein(a)","volume":"225","author":"Frischmann","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1194\/jlr.M500249-JLR200","article-title":"Lipoprotein [a] Is Cleared from the Plasma Primarily by the Liver in a Process Mediated by Apolipoprotein [a]","volume":"46","author":"Cain","year":"2005","journal-title":"J. Lipid Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pathol.2018.11.003","article-title":"Lipoprotein(a) Catabolism: A Case of Multiple Receptors","volume":"51","author":"McCormick","year":"2019","journal-title":"Pathology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0009-3084(94)90142-2","article-title":"Lp(a) Catabolism in Hypercholesterolaemic Individuals","volume":"67\u201368","author":"Knight","year":"1994","journal-title":"Chem. Phys. Lipids"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1172\/JCI110896","article-title":"Studies on the Role of Specific Cell Surface Receptors in the Removal of Lipoprotein (a) in Man","volume":"71","author":"Krempler","year":"1983","journal-title":"J. Clin. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0022-2275(20)37595-7","article-title":"Interaction of a Recombinant Form of Apolipoprotein[a] with Human Fibroblasts and with the Human Hepatoma Cell Line HepG2","volume":"37","author":"Tam","year":"1996","journal-title":"J. Lipid Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI114602","article-title":"Overexpression of Human Low Density Lipoprotein Receptors Leads to Accelerated Catabolism of Lp(a) Lipoprotein in Transgenic Mice","volume":"85","author":"Hofmann","year":"1990","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0022-2275(20)37140-6","article-title":"Cellular Uptake of Lipoprotein[a] by Mouse Embryonic Fibroblasts via the LDL Receptor and the LDL Receptor-Related Protein","volume":"38","author":"Reblin","year":"1997","journal-title":"J. Lipid Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1172\/JCI117794","article-title":"The Low Density Lipoprotein Receptor Is Not Required for Normal Catabolism of Lp(a) in Humans","volume":"95","author":"Rader","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0021-9150(91)90025-X","article-title":"Catabolism of Lipoprotein(a) in Familial Hypercholesterolaemic Subjects","volume":"87","author":"Knight","year":"1991","journal-title":"Atherosclerosis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"ref_40","first-page":"e48","article-title":"Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement from the American Heart Association","volume":"42","author":"Ginsberg","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, Function, and Genetics of Lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"17793","DOI":"10.1074\/jbc.273.28.17793","article-title":"Apolipoprotein(a) Synthesis and Secretion from Hepatoma Cells Is Coupled to Triglyceride Synthesis and Secretion","volume":"273","author":"Nassir","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1016\/S0021-9258(17)37076-X","article-title":"Molecular Basis for \u201cNull\u201d Lipoprotein(a) Phenotypes and the Influence of Apolipoprotein(a) Size on Plasma Lipoprotein(a) Level in the Baboon","volume":"269","author":"White","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0022-2275(20)32192-1","article-title":"Inhibition of N-Linked Glycosylation Results in Retention of Intracellular Apo[a] in Hepatoma Cells, Although Nonglycosylated and Immature Forms of Apolipoprotein[a] Are Competent to Associate with Apolipoprotein B-100 in Vitro","volume":"39","author":"Bonen","year":"1998","journal-title":"J. Lipid Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI117126","article-title":"Variation in Lipoprotein(a) Concentration Associated with Different Apolipoprotein(a) Alleles","volume":"93","author":"Perombelon","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/ATVBAHA.118.310865","article-title":"Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns","volume":"38","author":"Erhart","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/ATVBAHA.120.314965","article-title":"Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels\u2014Brief Report","volume":"41","author":"Hoekstra","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and Cardiovascular Disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A Genome-Wide Association Meta-Analysis on Lipoprotein (a) Concentrations Adjusted for Apolipoprotein (a) Isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J. Lipid Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Coassin, S., Hermann-Kleiter, N., Haun, M., Wahl, S., Wilson, R., Paulweber, B., Kunze, S., Meitinger, T., Strauch, K., and Peters, A. (2020). A Genome-Wide Analysis of DNA Methylation Identifies a Novel Association Signal for Lp(a) Concentrations in the LPA Promoter. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232073"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/FJC.0000000000001634","article-title":"Peroxisome Proliferator-Activated Receptor Gamma Regulates Interleukin-6-Induced Lipoprotein (a) Gene Expression in Human HepG2 Cells","volume":"84","author":"Harb","year":"2024","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-Genetic Influences on Lipoprotein(a) Concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.maturitas.2017.02.009","article-title":"The Effect of Hormone Replacement Therapy and Tibolone on Lipoprotein (a) Concentrations in Postmenopausal Women: A Systematic Review and Meta-Analysis","volume":"99","author":"Anagnostis","year":"2017","journal-title":"Maturitas"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","article-title":"Meta-Analysis: Effect of Hormone-Replacement Therapy on Components of the Metabolic Syndrome in Postmenopausal Women","volume":"8","author":"Salpeter","year":"2006","journal-title":"Diabetes Obes. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-119-4-199308150-00002","article-title":"Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome","volume":"119","author":"Wanner","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"dgaa672","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-Analysis","volume":"105","author":"Kotwal","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) Serum Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0272-6386(99)70147-2","article-title":"Apolipoprotein(a) Phenotypes and Lipoprotein(a) Concentrations in Patients with Renal Failure","volume":"33","author":"Milionis","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0021-9150(94)90006-X","article-title":"Reduced Serum Lipoprotein(a) Levels in Patients with Primary Biliary Cirrhosis","volume":"105","author":"Gregory","year":"1994","journal-title":"Atherosclerosis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1194\/jlr.M051664","article-title":"Thyroid Hormone Reduces PCSK9 and Stimulates Bile Acid Synthesis in Humans","volume":"55","author":"Bonde","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0009-8981(94)90178-3","article-title":"Relationship between Lipoprotein(a) Levels in Serum and Some Indices of Protein Synthesis in Liver Cirrhosis","volume":"224","author":"Alessandri","year":"1994","journal-title":"Clin. Chim. Acta"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14796678.2025.2451545","article-title":"Air Pollution and Coronary Atherosclerosis","volume":"21","author":"Scarica","year":"2025","journal-title":"Future Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gao, Y., Li, C., Huang, L., Huang, K., Guo, M., Zhou, X., and Zhang, X. (2023). Effects of Ambient Particulate Exposure on Blood Lipid Levels in Hypertension Inpatients. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1106852"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e70133","DOI":"10.1111\/eci.70133","article-title":"The Biology of Lipoprotein(a): From Genetics to Molecular Mechanisms","volume":"56","author":"Atallah","year":"2026","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized Phospholipid Modification of Lipoprotein(a): Epidemiology, Biochemistry and Pathophysiology","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cmet.2010.09.010","article-title":"Atherogenic Lipids and Lipoproteins Trigger CD36-TLR2-Dependent Apoptosis in Macrophages Undergoing Endoplasmic Reticulum Stress","volume":"12","author":"Seimon","year":"2010","journal-title":"Cell Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1074\/jbc.M309705200","article-title":"The Apolipoprotein(a) Component of Lipoprotein(a) Stimulates Actin Stress Fiber Formation and Loss of Cell-Cell Contact in Cultured Endothelial Cells","volume":"279","author":"Pellegrino","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1194\/jlr.M500555-JLR200","article-title":"Specific Monocyte Adhesion to Endothelial Cells Induced by Oxidized Phospholipids Involves Activation of cPLA2 and Lipoxygenase","volume":"47","author":"Huber","year":"2006","journal-title":"J. Lipid Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1194\/jlr.M060210","article-title":"Mechanistic Insights into Lp(a)-Induced IL-8 Expression: A Role for Oxidized Phospholipid Modification of Apo(a)","volume":"56","author":"Scipione","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","article-title":"Oxidized Phospholipids in Cardiovascular Disease","volume":"21","author":"Tsimikas","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lorey, M.B., Youssef, A., \u00c4ik\u00e4s, L., Borrelli, M., Hermansson, M., Assini, J.M., Kemppainen, A., Ruhanen, H., Ruuth, M., and Matikainen, S. (2023). Lipoprotein(a) Induces Caspase-1 Activation and IL-1 Signaling in Human Macrophages. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1130162"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans","volume":"134","author":"Bekkering","year":"2016","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/CIRCRESAHA.111.256859","article-title":"Role of Phospholipid Oxidation Products in Atherosclerosis","volume":"111","author":"Lee","year":"2012","journal-title":"Circ. Res."},{"key":"ref_74","first-page":"1","article-title":"The Apolipoprotein(a) Component of Lipoprotein(a) Mediates Binding to Laminin: Contribution to Selective Retention of Lipoprotein(a) in Atherosclerotic Lesions","volume":"1687","author":"Geroldi","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12944-025-02600-y","article-title":"Lipoprotein(a) and Panvascular Disease","volume":"24","author":"Xu","year":"2025","journal-title":"Lipids Health Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/14017431.2019.1612087","article-title":"Lipoprotein(a) Is Not Associated with Venous Thromboembolism Risk","volume":"53","author":"Kunutsor","year":"2019","journal-title":"Scand. Cardiovasc. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0037-1615654","article-title":"Binding of Recombinant Apolipoprotein(a) to Human Platelets and Effect on Platelet Aggregation","volume":"85","author":"Rivera","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e014611","DOI":"10.1161\/CIRCIMAGING.122.014611","article-title":"Association of Lipoprotein (a) with Coronary-Computed Tomography Angiography-Assessed High-Risk Coronary Disease Attributes and Cardiovascular Outcomes","volume":"15","author":"Dai","year":"2022","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.phrs.2017.02.001","article-title":"Lipoprotein(a) and Inflammation: A Dangerous Duet Leading to Endothelial Loss of Integrity","volume":"119","author":"Pirro","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e07","DOI":"10.15420\/ecr.2025.66","article-title":"Presumed Mechanisms Underlying Lipoprotein(a)-Caused Atherosclerosis","volume":"21","author":"Filtz","year":"2026","journal-title":"Eur. Cardiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/01.ATV.18.6.984","article-title":"Dominant Negative Effect of TGF-Beta1 and TNF-Alpha on Basal and IL-6-Induced Lipoprotein(a) and Apolipoprotein(a) mRNA Expression in Primary Monkey Hepatocyte Cultures","volume":"18","author":"Ramharack","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Kostner, K., Kostner, G.M., and Toth, P.P. (2023). Physiological Roles and Functions of Lipoprotein(a). Lipoprotein(a), Springer International Publishing.","DOI":"10.1007\/978-3-031-24575-6"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2023.09.001","article-title":"Lipoprotein(a), Interleukin-6 Inhibitors, and Atherosclerotic Cardiovascular Disease: Is There an Association?","volume":"54","author":"Makris","year":"2023","journal-title":"Atheroscler. Plus"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Cappannoli, L., Galli, M., Borovac, J.A., Valeriani, E., Animati, F.M., Fracassi, F., and Burzotta, F. (2024). Editorial: Inflammation in Ischemic Heart Disease: Pathophysiology, Biomarkers, and Therapeutic Implications. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1469413"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e033654","DOI":"10.1161\/JAHA.123.033654","article-title":"Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk","volume":"13","author":"Volgman","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/01.RES.78.4.615","article-title":"Specific Accumulation of Lipoprotein(a) in Balloon-Injured Rabbit Aorta in Vivo","volume":"78","author":"Nielsen","year":"1996","journal-title":"Circ. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1194\/jlr.M036343","article-title":"MCP-1 Binds to Oxidized LDL and Is Carried by Lipoprotein(a) in Human Plasma","volume":"54","author":"Wiesner","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/art.24448","article-title":"Induction of CCR2-Dependent Macrophage Accumulation by Oxidized Phospholipids in the Air-Pouch Model of Inflammation","volume":"60","author":"Kadl","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients with Aortic Stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacc.2008.09.052","article-title":"Pro-Osteogenic Phenotype of Human Aortic Valve Interstitial Cells Is Associated with Higher Levels of Toll-like Receptors 2 and 4 and Enhanced Expression of Bone Morphogenetic Protein 2","volume":"53","author":"Yang","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI119753","article-title":"The Atherogenic Lipoprotein Lp(a) Is Internalized and Degraded in a Process Mediated by the VLDL Receptor","volume":"100","author":"Argraves","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/07853890.2020.1775287","article-title":"Lipoprotein(a) in Atherosclerosis: From Pathophysiology to Clinical Relevance and Treatment Options","volume":"52","author":"Zavrtanik","year":"2020","journal-title":"Ann. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1093\/clinchem\/44.11.2301","article-title":"Lipoprotein(a) as a Risk Factor for Ischemic Heart Disease: Metaanalysis of Prospective Studies","volume":"44","author":"Craig","year":"1998","journal-title":"Clin. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups","volume":"139","author":"McQueen","year":"2019","journal-title":"Circulation"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol\u2013Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"117405","DOI":"10.1016\/j.atherosclerosis.2023.117405","article-title":"The Association of Lipoprotein (a) with Coronary Artery Calcification: A Systematic Review and Meta-Analysis","volume":"388","author":"Qiu","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"154706","DOI":"10.1016\/j.metabol.2021.154706","article-title":"Lipoprotein (a) and Coronary Artery Calcification: Prospective Study Assessing Interactions with Other Risk Factors","volume":"116","author":"Ong","year":"2021","journal-title":"Metabolism"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"ehae666.2829","DOI":"10.1093\/eurheartj\/ehae666.2829","article-title":"Lipoprotein(a) as a Predictive Marker of Coronary Artery Calcification (CAC). The Results from the STAR-Lp(a) Cohort Study","volume":"45","author":"Burzynska","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent Association of Lipoprotein(a) and Coronary Artery Calcification with Atherosclerotic Cardiovascular Risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/eurjpc\/zwae043","article-title":"The Association of Lipoprotein(a) and Coronary Artery Calcium in Asymptomatic Patients: A Systematic Review and Meta-Analysis","volume":"31","author":"Martignoni","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated Lipoprotein(a) and Risk of Ischemic Stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1161\/CIRCULATIONAHA.119.041080","article-title":"Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey","volume":"140","author":"Iung","year":"2019","journal-title":"Circulation"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMe0807001","article-title":"Calcific Aortic Stenosis\u2014Time to Look More Closely at the Valve","volume":"359","author":"Otto","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(09)60211-7","article-title":"Aortic Stenosis","volume":"373","author":"Carabello","year":"2009","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1186\/s40001-025-03071-8","article-title":"Association of Lipoprotein(a) and LPA Gene with Calcific Aortic Valve Disease","volume":"30","author":"Yu","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic Associations with Valvular Calcification and Aortic Stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/cvr\/cvad062","article-title":"Lipoprotein(a) and Calcific Aortic Valve Disease Initiation and Progression: A Systematic Review and Meta-Analysis","volume":"119","author":"Pantelidis","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"101746","DOI":"10.1016\/j.cpcardiol.2023.101746","article-title":"Association of Aortic Valve Calcification and High Levels of Lipoprotein (a): Systematic Review and Meta-Analysis","volume":"48","author":"Motawea","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2019.1581","article-title":"Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification","volume":"4","author":"Perrot","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Writing Committee Members, Blumenthal, R.S., Morris, P.B., Gaudino, M., Johnson, H.M., Anderson, T.S., Bittner, V.A., Blankstein, R., Brewer, L.C., and Cho, L. (2026). 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 153, e1154\u2013e1276.","DOI":"10.1161\/CIR.0000000000001423"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights from the FOURIER Trial","volume":"139","author":"Fazio","year":"2019","journal-title":"Circulation"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the Management of Chronic Coronary Syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41569-026-01249-z","article-title":"Residual Cardiovascular Risk in Coronary Artery Disease: From Pathophysiology to Established and Novel Therapies","volume":"23","author":"Galli","year":"2026","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Abdalla, H.M., Mahmoud, A.K., Khedr, A.E., Farina, J.M., Scalia, I.G., Abbas, M.T., Awad, K.A., Baba Ali, N., Bismee, N.N., and Attaripour Esfahani, S. (2024). Lipoprotein (a) as a Cardiovascular Risk Factor in Controversial Clinical Scenarios: A Narrative Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252011029"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjcard.2014.10.015","article-title":"Impact of Lipoprotein(a) as Residual Risk on Long-Term Outcomes in Patients after Percutaneous Coronary Intervention","volume":"115","author":"Konishi","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_120","first-page":"e61069","article-title":"Impact of Elevated Lipoprotein A on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis","volume":"16","author":"Sinha","year":"2024","journal-title":"Cureus"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjcard.2021.12.014","article-title":"Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients with Acute Coronary Syndrome Treated with Statins","volume":"168","author":"Takahashi","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.numecd.2022.03.024","article-title":"Impact of Lipoprotein(a) Concentrations on Long-Term Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Large Cohort Study","volume":"32","author":"Cui","year":"2022","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jacl.2023.05.094","article-title":"Association between Lipoprotein(a) and Long-Term Outcomes after Percutaneous Coronary Intervention for Lesions with in-Stent Restenosis","volume":"17","author":"Zhang","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/eurjpc\/zwae212","article-title":"Lipoprotein(a) and Long-Term in-Stent Restenosis after Percutaneous Coronary Intervention","volume":"31","author":"Mahmoud","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2022.10.013","article-title":"Lipoprotein(a), High-Sensitivity C-Reactive Protein, and Cardiovascular Risk in Patients Undergoing Percutaneous Coronary Intervention","volume":"363","author":"Yuan","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10554-022-02736-3","article-title":"Lipoprotein (a) Is Related to In-Stent Neoatherosclerosis Incidence Rate and Plaque Vulnerability: Optical Coherence Tomography Study","volume":"39","author":"Yuan","year":"2023","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.2147\/IJGM.S533584","article-title":"Elevated Lipoprotein(a) Predicts Stent Edge Restenosis and Adverse Two-Year Outcomes After PCI: An Intravascular Ultrasound Study","volume":"18","author":"Wu","year":"2025","journal-title":"Int. J. Gen. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.5551\/jat.38794","article-title":"Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention","volume":"24","author":"Suwa","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e70025","DOI":"10.1002\/clc.70025","article-title":"LDL-C and Hs-CRP Jointly Modify the Effect of Lp(a) on 5-Year Death in Patients with Percutaneous Coronary Intervention","volume":"47","author":"Li","year":"2024","journal-title":"Clin. Cardiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1093\/eurheartj\/ehaf194","article-title":"2025 ESC\/EACTS Guidelines for the Management of Valvular Heart Disease","volume":"46","author":"Praz","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jacc.2022.06.002","article-title":"Standardized Definitions for Bioprosthetic Valve Dysfunction Following Aortic or Mitral Valve Replacement","volume":"80","author":"Pibarot","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jacc.2025.06.049","article-title":"The Pathophysiologic Basis and Management of Calcific Aortic Valve Stenosis","volume":"86","author":"Desai","year":"2025","journal-title":"JACC"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","article-title":"Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis","volume":"9","author":"Arsenault","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/eurheartj\/ehaa1066","article-title":"Lipoprotein(a), LDL-Cholesterol, and Hypertension: Predictors of the Need for Aortic Valve Replacement in Familial Hypercholesterolaemia","volume":"42","author":"Watts","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"101264","DOI":"10.1016\/j.jacadv.2024.101264","article-title":"Lipoprotein(a) Levels in Severe Aortic Stenosis Referred for Transcatheter Aortic Valve Implantation Compared to Controls","volume":"3","author":"Loewenstein","year":"2024","journal-title":"JACC Adv."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00392-024-02587-z","article-title":"The Influence of Lipoprotein(a) on Aortic Valve Calcification in Patients Undergoing Transcatheter Aortic Valve Replacement","volume":"114","author":"Bormann","year":"2025","journal-title":"Clin. Res. Cardiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jacl.2025.03.001","article-title":"Association between Lipoprotein(a) and Long-Term Prognosis in Patients Receiving Transcatheter Aortic Valve Replacement","volume":"19","author":"Hu","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcmg.2017.02.005","article-title":"Systematic CT Methodology for the Evaluation of Subclinical Leaflet Thrombosis","volume":"10","author":"Jilaihawi","year":"2017","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e035597","DOI":"10.1161\/JAHA.124.035597","article-title":"Lipoprotein(a) and High-Sensitivity C-Reactive Protein Compound the Risk of Hypoattenuating Leaflet Thickening After Transcatheter Aortic Valve Replacement","volume":"13","author":"Shi","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/heartjnl-2023-322987","article-title":"Role of Lipoprotein(a) Concentrations in Bioprosthetic Aortic Valve Degeneration","volume":"110","author":"Farina","year":"2024","journal-title":"Heart"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e031322","DOI":"10.1161\/JAHA.123.031322","article-title":"Impact of High Lipoprotein(a) on Long-Term Survival Following Coronary Artery Bypass Grafting","volume":"13","author":"Yuan","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.atherosclerosis.2014.05.944","article-title":"Lipoprotein(a) Level and Apolipoprotein(a) Phenotype as Predictors of Long-Term Cardiovascular Outcomes after Coronary Artery Bypass Grafting","volume":"235","author":"Ezhov","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-5223(03)00365-9","article-title":"Association of Lipoprotein(a) Excess with Early Vein Graft Occlusions in Middle-Aged Men Undergoing Coronary Artery Bypass Surgery","volume":"126","author":"Pokrovsky","year":"2003","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/hrt.78.2.131","article-title":"Serum Lp(a) Lipoprotein Concentration Is Not Associated with Clinical and Angiographic Outcome Five Years after Coronary Artery Bypass Graft Surgery","volume":"78","author":"Skinner","year":"1997","journal-title":"Heart"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/ehjci\/jeac274","article-title":"Serum Lipoprotein(a) and Bioprosthetic Aortic Valve Degeneration","volume":"24","author":"Botezatu","year":"2023","journal-title":"Eur. Heart J.-Cardiovasc. Imaging"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Syryca, F., Krefting, J., Oertel, E., Wirth, F., Pellegrini, C., Rheude, T., Mayr, N.P., Holdenrieder, S., Alvarez-Covarrubias, H.A., and Von Scheidt, M. (2026). Impact of Lipoprotein(a) on the Durability of Aortic Bioprosthetic Valves. Clin. Res. Cardiol.","DOI":"10.1007\/s00392-026-02933-3"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ehjci\/jeaf320","article-title":"Lipoprotein(a) and Long-Term Structural Valve Degeneration of Aortic Bioprostheses","volume":"27","author":"Boute","year":"2026","journal-title":"Eur. Heart J.-Cardiovasc. Imaging"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"120420","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"META-LIPID Group Effect of Lipid-Lowering Therapies on Lipoprotein(a) Levels: A Comprehensive Meta-Analysis of Randomized Controlled Trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11789-017-0082-3","article-title":"Pro(a)LiFe-Study Group Prevention of Cardiovascular Complications in Patients with Lp(a)-Hyperlipoproteinemia and Progressive Cardiovascular Disease by Long-Term Lipoprotein Apheresis According to German National Guidelines","volume":"12","author":"Klingel","year":"2017","journal-title":"Clin. Res. Cardiol. Suppl."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein Apheresis to Treat Elevated Lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","article-title":"AMG145, a Monoclonal Antibody against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled Study of the Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibition with Evolocumab on Lipoprotein(a) Particle Kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"876","DOI":"10.5551\/jat.64454","article-title":"Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15","volume":"31","author":"Yamashita","year":"2024","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of Low Density Lipoprotein-Cholesterol and Cardiovascular Events with Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Statins: An Analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (Cholesteryl Ester Transfer Protein) Inhibition with Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Rehman, W.U., Yarkoni, M., Ilyas, M.A., Athar, F., Javaid, M., Ehsan, M., Khalid, M.T., Pasha, A., Selma, A.B., and Yarkoni, A. (2024). Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J. Cardiovasc. Dev. Dis., 11.","DOI":"10.3390\/jcdd11050152"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of Extended-Release Niacin on Plasma Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","article-title":"Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients","volume":"35","author":"Croyal","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1194\/jlr.R053066","article-title":"Current Therapies for Lowering Lipoprotein (a)","volume":"57","author":"Stroes","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"(2014). The HPS2-THRIVE Collaborative Group. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N. Engl. J. Med., 371, 203\u2013212.","DOI":"10.1056\/NEJMoa1300955"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"The AIM-HIGH Investigators (2011). Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N. Engl. J. Med., 365, 2255\u20132267.","DOI":"10.1056\/NEJMoa1107579"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"Rosenson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran\u2014A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The Chemical Evolution of Oligonucleotide Therapies of Clinical Utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjcard.2025.02.034","article-title":"Lipoprotein(a)\u2014From Biomarker to Therapy: A Review for the Clinician","volume":"245","author":"Jha","year":"2025","journal-title":"Am. J. Cardiol."},{"key":"ref_172","unstructured":"(2026). A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)."},{"key":"ref_173","unstructured":"Eli Lilly and Company (2026). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event\u2014ACCLAIM-Lp(a)."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40259-024-00665-2","article-title":"Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs","volume":"38","author":"Sang","year":"2024","journal-title":"BioDrugs"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Maloberti, A., Fabbri, S., Colombo, V., Gualini, E., Monticelli, M., Daus, F., Busti, A., Galasso, M., De Censi, L., and Algeri, M. (2022). Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010170"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40256-021-00499-1","article-title":"A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent","volume":"22","author":"Hardy","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering with Pelacarsen on Major Cardiovascular Events in Patients with CVD and Elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am. Heart J."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41586-024-07387-z","article-title":"Discovery of Potent Small-Molecule Inhibitors of Lipoprotein(a) Formation","volume":"629","author":"Diaz","year":"2024","journal-title":"Nature"},{"key":"ref_179","unstructured":"Eli Lilly and Company (2026). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Ambardekar, A.V., Bhatt, A., Hoekstra, M., Kelly, M.A., Musunuru, K., and Natarajan, P. (JACC, 2026). Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement, JACC, in press.","DOI":"10.1016\/j.jacc.2026.02.5092"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"A4139206","DOI":"10.1161\/circ.150.suppl_1.4139206","article-title":"Design of Heart-2: A Phase 1b Clinical Trial of VERVE-102, an in vivo Base Editing Medicine Delivered by a GalNAc-LNP and Targeting PCSK9 to Durably Lower LDL Cholesterol","volume":"150","author":"Vafai","year":"2024","journal-title":"Circulation"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Wan, P., Tang, S., Lin, D., Lu, Y., Long, M., Xiao, L., Jiang, Y., Liao, J., Ma, X., and Liu, Y. (2025). Base Editing Gene Therapy for Heterozygous Familial Hypercholesterolemia. medRxiv.","DOI":"10.1101\/2025.04.17.25325983"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa2511778","article-title":"Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3","volume":"393","author":"Laffin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., and Chen, Y.E. (2026). Gene Editing Therapies Targeting Lipid Metabolism for Cardiovascular Disease: Tools, Delivery Strategies, and Clinical Progress. Cells, 15.","DOI":"10.3390\/cells15020134"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1093\/eurheartj\/ehag092","article-title":"Lipoprotein(a)-Lowering Therapies: A Promising Future","volume":"47","author":"Zhang","year":"2026","journal-title":"Eur. Heart J."},{"key":"ref_186","first-page":"A17013","article-title":"CTX320: An Investigational in Vivo CRISPR-Based Therapy Efficiently and Durably Reduces Lipoprotein (a) Levels in Non-Human Primates After a Single Dose","volume":"148","author":"Morrow","year":"2023","journal-title":"Circulation"},{"key":"ref_187","unstructured":"Novartis Pharmaceuticals (2026). A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering with Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Stevens, C.A.T., Barkas, F., Brandts, J., Kwilasi, S., Dharmayat, K.I., Elshorbagy, A., Karungi, I., Mahani, A., Sharabiani, M.T.A., and Vallejo-Vaz, A.J. (2026). Machine Learning-Driven Prioritization of Lipoprotein(a) Testing: Model Development and Validation. Eur. J. Prev. Cardiol., zwag185.","DOI":"10.1093\/eurjpc\/zwag185"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1093\/eurheartj\/ehaf411","article-title":"Gene Therapy and Genome Editing for Lipoprotein Disorders","volume":"46","author":"Gurevitz","year":"2025","journal-title":"Eur. Heart J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/5897\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:16:39Z","timestamp":1785244599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/5897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":190,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15155897"],"URL":"https:\/\/doi.org\/10.3390\/jcm15155897","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}